ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 0860

Activated protein C resistance and protein C antibodies in the antiphospholipid syndrome alliance for clinical trials and international networking (APS ACTION) clinical database and repository
Abstract Number: 1497

Acute Care Utilization in Patients with Antiphospholipid Syndrome and/or Systemic Lupus Erythematosus
Abstract Number: 0291

Acute onset inflammatory myositis: Clinical features and survival.
Abstract Number: 1739

Acute Transcriptomic Response of Synovium and Dorsal Root Ganglia to Joint Injury
Abstract Number: 2245

Add-on of Coronary Artery Calcium Score Significantly Improves the Risk Prediction of Cardiovascular Diseases in Patients with Rheumatoid Arthritis: From a Real-world Cohort Study
Abstract Number: 2176

Addressing Hesitancy in JAK Inhibitor Use: Outcomes from Continuing Medical Education Reveal Confidence-Knowledge Gaps Among Community Rheumatologists
Abstract Number: 1689

Addressing Perceived Discrimination in Lupus Care: Enhancing Patient Empowerment and Health Equity Through Education and Support
Abstract Number: 1916

Adherence to cervical cancer screening programs in women with Systemic Lupus Erythematosus
Abstract Number: 2201

Adherence to Reproductive Health Guidelines in Lupus Care: Insights from Patient and Physician Surveys
Abstract Number: LB07

Adipose-Tissue Derived Mesenchymal Stem Cells vs Hyaluronic Acid in Refractory Knee Osteoarthritis in a low-resource setting: A Phase IIb RCT
Abstract Number: 2206

Adolescents with Systemic Lupus Erythematosus at Highest Risk of Adverse Pregnancy Outcomes
Abstract Number: 0191

Advanced therapy use in RA patients with moderate disease activity in a large NHS Foundation Trust in South London, UK
Abstract Number: 1988

Advancing Vascular Assessment: Combining NIRS-VOT and Ultrasound-Based Brachial Artery Diameter for Improved Diagnostics in Healthy Controls and APS
Abstract Number: 1290

Adverse Childhood Experiences: Prevalence and Relationship to Disease and Mental Health Outcomes in Childhood-Onset Systemic Lupus Erythematosus (cSLE)
Abstract Number: LB06

AgAIN Study: First Head-to-Head Trial of Secukinumab vs. Ustekinumab in TNFα Inhibitor-Experienced Psoriatic Arthritis Patients Reveals Better Efficacy Across Multiple Domains

« Previous Page
1
…
6
7
8
9
10
…
182
Next Page »

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].